Download
1 / 4
40 likes | 272 Views
Clinical Effectiveness & High Cost Drugs. Introduction from Roelof Konterman Vice-Chairman of the Executive Board & Head of Health, Achmea. Current Members. Background. Initially two separate Panels, which both first met in December 2015, as High Cost Drugs and New Medical Technologies
E N D
Clinical Effectiveness & High Cost Drugs Introduction from Roelof Konterman Vice-Chairman of the Executive Board & Head of Health, Achmea
Background • Initially two separate Panels, which both first met in December 2015, as High Cost Drugs and New Medical Technologies • Now established as High Cost Drugs and Clinical Effectiveness, meeting at least once a year
Current issues • Topics discussed include, but are not limited to: - Volume of treatments needed to improve patient outcomes - How to grade and access the merit of new and existing technologies - Establishing where there is benefit for knee arthroscopy - Gaining a better understanding of when and how to obtain better value from robotic surgery (Da Vinci) - Comparing outcomes between “at home” treatments vs traditional hospital settings - The impact of political advocacy & communication relating to High Cost Drugs - Reviewing the pipeline of High Cost Drugs entering the market
